Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Cytotoxic T Lymphocyte Trafficking and Survival in an Augmented Fibrin Matrix Carrier

  • Zhaoxia Zou,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Erin Denny,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Christine E. Brown,

    Affiliation Department of Cancer Immunotherapeutics & Tumor Immunology, City of Hope National Medical Center, Duarte, California, United States of America

  • Michael C. Jensen,

    Affiliation Department of Cancer Immunotherapeutics & Tumor Immunology, City of Hope National Medical Center, Duarte, California, United States of America

  • Gang Li,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Tatsuhiro Fujii,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Josh Neman,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Rahul Jandial,

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America

  • Mike Chen

    Affiliation Division of Neurosurgery, City of Hope National Medical Center, Duarte, California, United States of America


Cell-based therapies have intriguing potential for the treatment of a variety of neurological disorders. One such example is genetically engineered cytotoxic T lymphocytes (CTLs) that are being investigated in brain tumor clinical trials. The development of methods for CTL delivery is critical to their use in the laboratory and clinical setting. In our study, we determined whether CTLs can migrate through fibrin matrices and if their migration, survival, and function could be modulated by adding chemokines to the matrix. Our results indicated that CTLs can freely migrate through fibrin matrices. As expected, the addition of the monocyte chemotactic protein-1 (MCP-1), also known as chemokine C-C motif ligand 2 (CCL2), to the surrounding media increased egress of the CTLs out of the fibrin clot. Interleukin (IL) -2 and/or IL-15 embedded in the matrix enhanced T cell survival and further promoted T cell migration. The interleukin-13 receptor alpha 2 specific (IL-13R alpha2) T cells that traveled out of the fibrin clot retained the capacity to kill U251 glioma cells. In summary, CTLs can survive and migrate robustly in fibrin matrices. These processes can be influenced by modification of matrix constituents. We conclude that fibrin matrices may be suitable T cell carriers and can be used to facilitate understanding of T cell interaction with the surrounding microenvironment.


Adoptive immunotherapy using genetically engineered cytotoxic T lymphocytes (CTLs) is being investigated as a potential treatment for cancer in the central nervous system and elsewhere [1], [2]. Pilot clinical trials have been initiated to evaluate the feasibility and safety of local-regional delivery of autologous IL13-zetakine redirected CTL clones in patients with recurrent glioblastoma (GBM). These results indicate the adoptive transfer of tumor-specific cytotoxic T cells to the tumor bed is a promising strategy, though its clinical application may be limited due to the shortcomings of previous and current delivery methods.

While systemic delivery is appealing for its convenience, non-specific targeting, high cell dosage requirements, and the presence of the blood-brain barrier are formidable obstacles. In clinical trials local delivery can be achieved using catheter-based delivery systems. Catheter-based delivery systems, however, are associated with risks such as infection and hemorrhage. Additionally, catheter-based delivery systems used at our institution present significant logistical challenges. First, injection results in the formation of a pocket of T cells at the catheter tip because cell sized particles cannot flow through the extracellular space. With point source distribution, CTLs may have to seek and find distant targets in the brain diminishing the chances of successful therapy. Second, to attain an adequate dose, multiple injections are needed. These multiple injections lengthen hospital stay creating more cost, risk, and patient inconvenience. We hypothesized that T cells could be delivered more efficiently by embedded them in a fibrin matrix placed in the resection cavity during surgery. The fibrin matrix is a commercially available (Baxter, Tisseel) biodegradable adhesive obtained by a combination of human-derived fibrinogen and thrombin, duplicating the last step of the coagulation cascade. Tisseel is normally used in neurosurgery as a dural sealant and a hemostatic agent. Studies have shown that the application of fibrin glue to the brain is safe and well tolerated [3], [4], [5].

Our approach of using fibrin glue as a vehicle for CTLs has not been previously described, though fibrin glue has been widely used for delivery of a variety of cells [6], [7], [8], [9], [10], [11], [12], [13], [14], [15]. Fibrin matrices are employed not only as a cell carrier, but also as suitable vectors for drugs and exogenous growth factors. Therefore, there exists the potential to combine cell-based therapies with modulating biological factors in the fibrin glue.

A prerequisite for use of fibrin matrices as a T cell delivery vehicle is that the cells must be able to migrate out of the fibrin clot. Additionally, these cells must survive the passage and remain efficacious tumor killers. In this study, we demonstrated the ability of T cells to robustly migrate through a bio-enhanced matrix while maintaining potency against glioma cells.

Materials and Methods


Recombinant human interleukin (IL) -2 was purchased from Cell signaling. Recombinant human IL-15 and monocyte chemotactic protein-1 (MCP-1) were purchased from R&D Systems (Minneapolis, MN). Each cytokine and chemokine was reconstituted in PBS with 0.1% human serum albumin (PBS–HSA) and stored at −20°C until time of use. On the day of experimentation, aliquots were diluted in RPMI media to the final concentrations as indicated.

Cell lines and Cultures

In our experiments, firefly luciferase (ffl+) expressing interleukin-13 receptor alpha 2 specific (IL-13R alpha2) CTLs cells were cultured in RPMI 1640 (Invitrogen) with 10% heat-inactivated fetal calf serum (FCS), 25 mmol/L HEPES, and 2 mmol/L L-glutamine supplemented with 50 U/mL rhIL-2 (Chiron). U251 glioblastoma cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated FCS, 25 mmol/L HEPES, and 2 mmol/L L-glutamine.

For conditioned medium, U251 cell lines were grown to 60–90% confluency and cells were then transferred to serum-free medium. 24 and 48 hours after the transfer, the cell-free supernatants were collected.

Fibrin Matrix (Tisseel) Formulation and Dissolution

The sealer protein component (fibrinogen-containing component) was reconstituted in aprotinin solution (Baxter Healthcare), and the thrombin component was reconstituted in 30 mM CaCl2. Both solutions were diluted to the appropriate concentration using Trisbuffered saline (TBS) and 30 mM CaCl2 in TBS for the sealer protein and thrombin components, respectively. Formulation 1 was composed of 2.5 mg/ml fibrinogen and 2.5 U/ml thrombin. Formulation 2 was composed of 5 mg/ml fibrinogen and 5 U/ml thrombin. Finally, Formulation 3 was composed of 5 mg/ml fibrinogen and 1 U/ml thrombin. In select experiments tissue plasminogen activator (tPA) was used to dissolve the fibrin clots to determine the number of remaining T cells. The CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed as a surrogate for cell count.

Incorporation of T Cells in Fibrin Matrix and Chemotaxis Assays

T cell/fibrin clot constructs were prepared in the following manner. Following harvest with trypsin–EDTA, 100 µl of ffl+ IL-13 zetakine CTLs (7.5*106 cells/mL) were mixed with 150 µl sealer protein solution. 150 µl of thrombin solution was subsequently added to the sealer protein–cell solution and mixed by tapping and tilting the plates. Then 400 µl of the combined mixture was placed in 24-well 5 µm QCM Chemotaxis Cell Migration Assay plates (Millipore). Plates were incubated in a 5% CO2 incubator for 8, 24, or 48 hours. At each time point, the number of T cells that migrated out of the clots from the upper chamber to the lower chamber was assayed using the CellTiter-Glo Luminescent Cell Viability kit and measured using a luminescence plate reader. The number of T cells that had migrated out of the fibrin matrix was calculated according to the standard curve; then the percent migration was calculated by dividing the number of collected T cells by number of initial T cells placed in the clot and multiplying the result by 100. Cytotoxicity of IL-13 zetakine CTLs passage through the fibrin matrix may adversely affect the ability of CTLs to kill tumor cells. The potency of the CTLs was assayed in the following manner. Effector cells were used 13 to 15 days after stimulation with muromonab-CD3 (OKT3) and irradiated feeder cells. 7.5×105 IL-13 zetakine CTLs per fibrin clot were plated into the upper chamber of 24 well chemotaxis assay plates. The CTLs that had migrated out were collected after 24 hours. U251 ffl+ target cells (200,000 cells/ml) were co-cultured with increasing numbers of CD8+ effector zetakine CTLs in a 5% CO2 incubator. After 4 or 24 hours of incubation, Dual-Glo Luciferase Assay Reagent was added to each well of the 96-well plate. The plate was incubated for 10 minutes at room temperature, and luminescence was read from 8 mm above the bottom of the plate on the luminescence plate reader.

Human Chemokine Levels in Glioma-Conditioned Medium

Chemokine levels of MCP-1, C-C motif ligand 5 (CCL5), and C-X-C motif ligand 10 (CXCL10) were determined using their respective Human ELISA Kits (Invitrogen) as per the manufacturers' instructions. Briefly, samples, controls, MCP-1, CCL5 (data not shown), or CXCL10 standards were incubated for 2 hours at room temperature with a biotinylated Hu MCP-1, CCL5, or CXCL10 Biotin Conjugate solution, and then incubated for 30 minutes at room temperature with Streptavidin-HRP Working Solution. Absorbance detection of captured cytokines was quantified by Optical Density using a Microplate Reader.

Stimulation of T Cells in the Fibrin Clots and Effect on Survival and Migration

IL-2 and/or IL-15 were added to the fibrin matrix to investigate whether T cell survival and migration could be enhanced. T cell–fibrin clots were prepared as described above. IL-2 (500 u/ml), IL-15 (100 ng/ml), or IL-2 + Il-15 were mixed into the fibrin clots. The IL-2 and IL-15 concentrations were chosen based on previous studies and our preliminary experiments [16]. The CellTiter-Glo ATP assay was performed to quantify CTL migration after 24 hours.


The means and standard deviations of the obtained data were calculated. One-way analysis of variance (ANOVA) with post-hoc testing was used for comparing means of three or more variables. Statistical analysis was carried out using SAS software (SPSS version 12.0.1) on a Microsoft Windows XP system. The threshold for statistical significance was set at 0.05.


T Cell Migration Through Low Viscosity Fibrin Matrices

It is essential that CTLs are able to travel through the fibrin clot to reach their target. We examined the effect of viscosity on T cell migration using 6 formulations of varying thrombin and fibrinogen concentrations. T cells that had exited to the surrounding media were collected and quantified using an ATP assay as a surrogate of cell count. The CellTiter-Glo ATP assay showed a highly linear relationship between cell count and luminescence (R2 = .98; data not shown).

Formulation 1 of lower fibrinogen and thrombin concentrations was not only less viscous but also allowed the most T cells (25%) to move out of the fibrin glue (p<0.01) (Figure 1). Formulation 2 (5.0 mg/ml fibrinogen and 5.0 U/ml thrombin) and Formulation 3 (5.0 mg/ml and 1.0 U/ml) allowed only 5% of T cells to migrate through the clot. T cells were not capable of passaging through the fibrin matrix when concentrations of fibrinogen and thrombin exceeded 5.0 mg/ml and 1.0 U/ml respectively (data not shown). At concentrations lower than those reported in Formulations 1, the fibrin glue did not form a clot, and therefore these formulations were not further analyzed.

Figure 1. Effects of fibrin clot formulation and MCP-1 on T cell migration.

(A) Microscopic evaluation (10×) of T cell migration out of fibrin matrix. 7.5×105 T cells were mixed into a fibrin clot (Formulation 1). Substantial egress of T cells into surrounding media was visualized at 48 hours. (B) Effects of formulation and MCP-1 on CTL migration. CTLs were added to Tisseel clots with varying concentrations of thrombin and fibrinogen (Formulation 1–3). After 48 hours, ATP assays were performed to quantify the amount of CTLs able to migrate out of the clots and into the surrounding media. The matrix with the lowest viscosity (Formulation 1) allowed for the most T cell migration (* p<0.01). In addition to viscosity, effects of MCP-1 on migration were examined. For all formulations, the addition of MCP-1 to the surrounding media significantly increased T cell migration out of the clot (# p<0.01). The data represents the means ± SD of three independent experiments.

Chemoattractants in the Surrounding Media Increase CTL Migration Out of the Fibrin Clot

MCP-1 is a known T cell chemokine; its ability to penetrate into fibrin matrices, however, was unknown. We indirectly examined if MCP-1 could diffuse into the fibrin clot to promote CTL trafficking. As shown in Figure 1, the addition of MCP-1 to the media outside of the clot significantly increased CTL migration in the three formulations shown (p<0.01).

In addition to secreting other CTL chemokines such as IL-8, tumors can regulate activation of normal T cell expression and secretion [17]. The collective effect of these chemokines on T cell trafficking from the fibrin clot was assessed (Figure 2). CTLs in the fibrin matrices were exposed to standard culture media or conditioned media obtained from culturing U251 glioblastoma cells. There was significantly (p<0.05) more migration out of the clot when glioma-conditioned media was used.

Figure 2. Effect of media on T cell migration and quantification of viable T cells remaining in the fibrin matrix.

CTLs were mixed with Tisseel (Formulation 1) and cultured in either glioma-conditioned media (GC-Media) or standard culture media (Media). Quantification of cells performed 48 hours after incubation showed GC-Media to significantly increase T cell migration out of the fibrin matrix (* p<0.05). The combined total of cells remaining in and migrating outside the clot (reported as a percentage of the initial cell number) was approximately the same (∼30%) regardless of the type of media used. The data represents the means ± SD of three independent experiments.

The fate of T cells remaining in the clot was also assessed because it was unclear if those cells were trapped or had perished. The clots were dissolved with tPA, and the cells were quantified using an ATP assay (Figure 2). Regardless of the type of media, the total number of cells—CTLs in or out of the clot—was slightly over 30% of the initial cell count. This indicated that one limiting factor was T cell demise within the fibrin matrix.

Chemokine Level in Glioma-Conditioned Medium

We demonstrated that there was significantly more migration out of the clot when glioma-conditioned media was used compared to standard culture media. To further investigate the mechanism for the observed trafficking of T cells in glioma-conditioned media, we measured chemokine levels. MCP-1 and CXCL10 were detected at high levels in glioma-conditioned supernatants compared to standard culture media (p<0.01) (Figure 3). Thus, the observed migrational response in Figure 2 may be a consequence of chemokine-dependent directional migration.

Figure 3. Cytokine concentrations in glioma-conditioned media (GC-Media) and standard culture media (Media).

Cytokine concentrations were measured using Human ELISA Kits. (A) Increased MCP-1 concentrations in GC-Media (* p<0.0001, 24 h or 48 h vs. control). (B) Increased CXCL10 concentrations in GC-Media (* p<0.0001, 24 h or 48 h vs. control). The data represents the means ± SD of three independent experiments.

IL-2 and IL-15 Alone or in Combination Enhances T Cell Survival and Promotes Trafficking

Cell survival after implantation is a major concern. To enhance survival and potentiate trafficking, the cytokines IL-2 and IL-15, alone or in combination, were added to the fibrin matrix. Prior to this experiment, we confirmed that IL-2 and IL-15 caused expansion and an increase in the diameter of CTLs, the later reflective of T cell health (data not shown). Addition of IL-2 (500 u/ml), IL-15 (100 ng/ml), or IL-2+Il-15 into the fibrin clot dramatically (p<0.01) increased T cell egression at multiple time points (Figure 4). In contrast, the CTL migration in the untreated group decreased to almost 0% after 96 hours. The most trafficking was seen when IL-2 and IL-15 were combined; 65% of CTLs had migrated out. These findings suggest the proliferative effect of the cytokines is preserved in the fibrin matrix.

Figure 4. Effects of IL-2 and IL-15 on CTL migration.

IL-2 (500 u/ml), IL-15 (100 ng/ml), or the combination of IL-2/IL-15 was added into the fibrin clots (Formulation 1). ATP assays were performed to quantify the number of T cells that had migrated out of the clots after 24, 48, and 96 hours. T cell migration significantly increased out of treated clots containing IL-2, IL-15, or both compared to untreated clots. The data represents the means ± SD of three independent experiments (* p<0.01 IL-2, IL-15, or IL-2/IL-15 vs. untreated).

IL-13R alpha2 CTLs That Migrate Out of the Matrix Remain Potent Against U251 Glioma Cells

Whether CTLs are still potent after migrating out of the fibrin clot is unknown. U251 glioma cells expressing firefly luciferase (U251 ffl+) were co-cultured with increasing numbers of glioma-specific primary IL-13 zetakine CTLs that had migrated out of the fibrin matrix (Figure 5). Although U251 cells died in a time dependent manner, glioma cell death was dose-dependent (in terms of CTL to U251 ratio) only at a shorter treatment time (4 hours). 24 hours after incubation U251 cells were almost completely eradicated when cultured with a five fold greater number of CTLs.

Figure 5. Cytotoxicity of post-migration IL-13 zetakine CTLs.

Post-migration IL-13 zetakines were co-cultured with U251 glioma cells at a ratio (CTL∶U251) of 1∶1 or 5∶1. The viability of U251 cells was determined using the Dual-Glo Luciferase Assay after 4 hours (A) and 24 hours (B) of incubation time. Increasing the co-culture ratio to 5∶1 significantly decreased glioma cell survivability (* p<0.01). Regardless of the co-culture ratio, glioma cells died in a time-dependent manner (** p<0.001). The data represents the means ± SD of three independent experiments.


Adoptive immunotherapy is a theoretically elegant approach for the treatment of brain tumors; however, the optimal method to deliver T cells has not been developed. We hypothesized that in lieu of the catheter-based delivery system, T cells can be distributed by using a fibrin matrix carrier that is placed into the resection cavity at the time of surgery. This method would confer potential advantages. One is that the viscous nature of the substance improves localization of the T cells to the tumor bed, preventing washout into the subarachnoid space. Another potential advantage is that catheter implantation is not required and therefore certain risks are avoided. The most important potential benefits relate to dose and distribution. A much larger dose can be delivered. Additionally, bioactive reagents can be added to the fibrin matrix to enhance the survival and function of the T cells.

Our finding that CTLs can passage through low viscosity fibrin matrices is consistent with studies reporting migration through Tisseel of fibroblasts, chondrocytes, neutrophils and monocytes [18], [19], [20], [21]. The concentration of fibrinogen and thrombin that we determined as optimal (2.5 mg/ml fibrinogen and 2.5 U/ml thrombin) is similar to those reported in Cox et al.'s study which examined fibroblast migration through fibrin clots (5–17 mg/mL fibrinogen and 1–167 U/mL thrombin).

Though it was obvious that high concentrations of fibrinogen were inhibitory, the active or passive mechanism(s) responsible for CTL egress out of Tisseel have not been defined. In vivo, tumor cells secrete chemoattractants such as MCP-1 which play an important role in the host antitumor immune response by recruiting CD4+ and CD8+ cells [22], [23], [24]. It was uncertain if CTL chemotactic factors could diffuse from the surrounding media into the clot to promote migration. We have found that glioma cell line U251 produces sufficient levels of MCP-1 to chemoattract T cell migration through fibrin clots in vitro. Our data indicated that MCP-1 containing or glioma-conditioned media—the later theoretically full of MCP-1 and other chemokines—significantly enhanced T cell migration suggesting that targeting of remote tumor cells is possible.

We allow that factors other than MCP-1 can enhance T cell migration. Although no other study has examined CTL migration using a fibrin clot, Nishimura et al. have shown that chemokines such as CXCL10, also referred to as interferon gamma-induced protein 10 (IP-10), can play a critical role in the recruitment of Tc1 effector cells to the brain tumor site [25]. Our present study showed that CXCL10, in fact, was present in high concentrations in glioma-conditioned media and could potentially promote CTL migration out of the fibrin clot. In addition to the identity of chemokines, other variables such as the amount or type of chemokine-secreting residual tumor may be important.

Even under optimal circumstances, without additional aid only about one-fourth of the CTLs were able to leave the fibrin matrix. We observed that most had perished by days 3–6. Survival varied depending on the initial health of the T cells which corresponded to their status in the stimulation cycle. Of the T cells remaining in the matrix, over two thirds of the initial cells were no longer viable. Improving viability would be expected to increase migration due to an enlarged pool of available cells.

Adoptively transferred antigen-specific CTLs are highly dependent on exogenous cytokines such as IL-2, IL-7, IL-15 and IL-21 for their continued growth and survival [26]. Systemic administration of IL-2 has been used to enhance T cell expansion and persistence in vivo [27]. Administration of lowdose IL-15 has been shown to promote the persistence of adoptively transferred tumor-specific T cells in murine tumor models; however, the systemic toxicity and the expansion of unwanted cells, including regulatory T cells, limit the clinical value of this strategy [28], [29]. We demonstrated that IL-2 and IL-15 added to the fibrin clot improved survival, possibly caused proliferation, and subsequently increased T cell migration by 2–3 fold.

Migration to the target is insufficient if the T cells lose their capacity to kill the tumor cells during passage. IL-13 zetakine CTLs have been previously shown to recognize and kill glioblastomas and medulloblastomas expressing IL-13R alpha2 [30], [31]. In fact, IL-13 zetakine CTLs have been shown to recognize and eliminate brain tumor stem-like initiating cells [32]. Our data indicated that IL-13 zetakine CTLs that had moved out of the fibrin matrix killed U251 glioma cells in a time and dose dependent fashion. The optimal dose required in vivo has yet to be determined. However, the observed dose dependency suggests that larger doses possible with fibrin matrix delivery would confer a significant advantage.

We have shown that robust migration can be achieved with IL-2 and IL-15, chemotaxis mechanisms are not impaired by the matrix, and that CTLs that have passaged through the matrix remain potent. The significant logistical and biological advantages associated with this technique are promising but will need to be confirmed in vivo and in future clinical trials.


We are indebted to Araceli Naranjo who provided invaluable assistance with procurement of reagents for this study.

Author Contributions

Conceived and designed the experiments: ZZ ED MC. Performed the experiments: ZZ ED. Analyzed the data: GL JN RJ. Contributed reagents/materials/analysis tools: CEB MCJ. Wrote the paper: ZZ TF RJ MC.


  1. 1. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, et al. (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45: 77–87.
  2. 2. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233–240.
  3. 3. Ghulam Muhammad AK, Yoshimine T, Maruno M, Takemoto O, Hayakawa T (1997) Topical application of fibrin adhesive in the rat brain: effects on different cellular elements of the wound. Neurol Res 19: 84–88.
  4. 4. Kassam A, Nemoto E, Balzer J, Rao G, Welch WC, et al. (2004) Effects of Tisseel fibrin glue on the central nervous system of nonhuman primates. Ear Nose Throat J 83: 246–248, 250, 252 passim.
  5. 5. Lee KC, Park SK, Lee KS (1991) Neurosurgical application of fibrin adhesive. Yonsei Med J 32: 53–57.
  6. 6. Andrades P, Asiedu C, Rodriguez C, Goodwin J, Deckard LA, et al. (2007) Insulin secretion from pancreatic islets in fibrin glue clots at different fibrinogen and thrombin concentrations. Transplant Proc 39: 1607–1608.
  7. 7. Chen SJ, Chang CM, Tsai SK, Chang YL, Chou SJ, et al. (2010) Functional improvement of focal cerebral ischemia injury by subdural transplantation of induced pluripotent stem cells with fibrin glue. Stem Cells Dev 19: 1757–1767.
  8. 8. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, et al. (2004) Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 44: 654–660.
  9. 9. Currie LJ, Sharpe JR, Martin R (2001) The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 108: 1713–1726.
  10. 10. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, et al. (2007) Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 13: 1299–1312.
  11. 11. Hafez AT, Afshar K, Bagli DJ, Bahoric A, Aitken K, et al. (2005) Aerosol transfer of bladder urothelial and smooth muscle cells onto demucosalized colonic segments for porcine bladder augmentation in vivo: a 6-week experimental study. J Urol 174: 1663–1667; discussion 1667–1668.
  12. 12. Jung SN, Rhie JW, Kwon H, Jun YJ, Seo JW, et al. (2010) In vivo cartilage formation using chondrogenic-differentiated human adipose-derived mesenchymal stem cells mixed with fibrin glue. J Craniofac Surg 21: 468–472.
  13. 13. Rainer C, Wechselberger G, Bauer T, Neumeister MW, Lille S, et al. (2001) Transplantation of tracheal epithelial cells onto a prefabricated capsule pouch with fibrin glue as a delivery vehicle. J Thorac Cardiovasc Surg 121: 1187–1193.
  14. 14. Wechselberger G, Russell RC, Neumeister MW, Schoeller T, Piza-Katzer H, et al. (2002) Successful transplantation of three tissue-engineered cell types using capsule induction technique and fibrin glue as a delivery vehicle. Plast Reconstr Surg 110: 123–129.
  15. 15. Wechselberger G, Schoeller T, Stenzl A, Ninkovic M, Lille S, et al. (1998) Fibrin glue as a delivery vehicle for autologous urothelial cell transplantation onto a prefabricated pouch. J Urol 160: 583–586.
  16. 16. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, et al. (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181: 6738–6746.
  17. 17. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, et al. (2007) Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 179: 3332–3341.
  18. 18. Cox S, Cole M, Tawil B (2004) Behavior of human dermal fibroblasts in three-dimensional fibrin clots: dependence on fibrinogen and thrombin concentration. Tissue Eng 10: 942–954.
  19. 19. Gille J, Meisner U, Ehlers EM, Muller A, Russlies M, et al. (2005) Migration pattern, morphology and viability of cells suspended in or sealed with fibrin glue: a histomorphologic study. Tissue Cell 37: 339–348.
  20. 20. Hanson AJ, Quinn MT (2002) Effect of fibrin sealant composition on human neutrophil chemotaxis. J Biomed Mater Res 61: 474–481.
  21. 21. Mana M, Cole M, Cox S, Tawil B (2006) Human U937 monocyte behavior and protein expression on various formulations of three-dimensional fibrin clots. Wound Repair Regen 14: 72–80.
  22. 22. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91: 3652–3656.
  23. 23. Roth SJ, Carr MW, Springer TA (1995) C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol 25: 3482–3488.
  24. 24. Zheng M, Sun G, Cai S, Mueller R, Mrowietz U (1999) Significant reduction of T-cell chemotaxis to MCP-1 in patients with primary and metastatic melanoma. Chin Med J (Engl) 112: 493–496.
  25. 25. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, et al. (2006) Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66: 4478–4487.
  26. 26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708–712.
  27. 27. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, et al. (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 24: 363–373.
  28. 28. Blanco-Jerez C, Plaza JF, Masjuan J, Orensanz LM, Alvarez-Cermeno JC (2002) Increased levels of IL-15 mRNA in relapsing–remitting multiple sclerosis attacks. J Neuroimmunol 128: 90–94.
  29. 29. Roychowdhury S, May KF Jr, Tzou KS, Lin T, Bhatt D, et al. (2004) Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 64: 8062–8067.
  30. 30. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, et al. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160–9166.
  31. 31. Stastny MJ, Brown CE, Ruel C, Jensen MC (2007) Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. J Pediatr Hematol Oncol 29: 669–677.
  32. 32. Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, et al. (2009) Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69: 8886–8893.